TLSI
What one share of TriSalus Life Sciences holds
Surgical and Medical Instruments and Apparatus
We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications.
TriSalus Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.90 |
|---|---|
| Profit | −$1.14 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.47 |
| Cash and investments | $0.75 |
| Debt | $0.54 |
| Book value | $0.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $40.04 | −$161.55 | $2.12 | −$106.48 | — | −$509.11 |
| 2023 | $1.97 | −$6.77 | $0.06 | −$5.45 | — | — |
| 2024 | $1.16 | −$1.31 | $0.01 | −$1.63 | — | −$0.83 |
| 2025 | $1.19 | −$1.84 | $0.02 | −$0.50 | — | −$0.68 |